Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Ashkenazi will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee through July 2024
Subscribe To Our Newsletter & Stay Updated
